Related Experiment Video

Updated: Jul 20, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Ribozyme-mediated selective killing of cancer cells expressing carcinoembryonic antigen RNA by targeted

Heung-Su Jung1, Seong-Wook Lee

  • 1Department of Molecular Biology, Institute of Nanosensor and Biotechnology, Dankook University, Seoul 140-714, Republic of Korea.

Biochemical and Biophysical Research Communications
|September 2, 2006
PubMed

Insights

Researchers developed a novel ribozyme targeting carcinoembryonic antigen (CEA) RNA. This ribozyme selectively triggers gene therapy in cancer cells, offering a promising approach for targeted cancer treatment.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetic Engineering

Background:

  • Carcinoembryonic antigen (CEA) is implicated in tumor progression, including metastasis and immune evasion.
  • CEA's role in neoplasia makes it a potential therapeutic target for anti-cancer strategies.

Purpose of the Study:

  • To develop a specific ribozyme targeting CEA RNA for selective cancer gene therapy.
  • To reprogram RNA in CEA-expressing cells to trigger transgene activity and reduce CEA levels.

Main Methods:

  • Development of a trans-splicing ribozyme designed to target CEA RNA.
  • Utilizing the ribozyme to induce transgene expression and reduce endogenous CEA RNA levels.
  • Delivery of a suicide gene (herpes simplex virus thymidine kinase) into CEA-expressing cancer cells.

Main Results:

  • The ribozyme achieved accurate and specific RNA replacement via trans-splicing in CEA-expressing cells.
  • Significant reduction in targeted CEA RNA expression was observed.
  • Selective delivery of suicide gene activity led to specific retardation of cancer cell survival upon ganciclovir treatment.

Conclusions:

  • CEA RNA-targeting trans-splicing ribozymes demonstrate potential as effective genetic agents for cancer gene therapy.
  • This approach enables selective gene expression and cancer cell killing in CEA-expressing tumors.
  • The developed ribozyme offers a precise method for targeting cancer cells based on CEA RNA expression.

More Related Videos

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Ribozymes02:47

Ribozymes

The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can be...
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...